About Us
Vice Chairwoman of the Board, Executive Director: Ms. Cheng Cheung Ling
-
- Vice Chairwoman of the Board, Executive Director: Ms. Cheng Cheung Ling
- Ms. Cheng Cheung Ling is one of the founders of the Company, currently serving as Vice Chairwoman of the Board, an Executive Director, and a member of the Executive Board Committee. Ms. Cheng was born in 1964, graduated from the Guanghua School of Management at Peking University with a Master Degree in Business Administration. She is also a clinician. She has extensive experience and a discerning vision for management and investment in the pharmaceutical industry, and spares no effort in promoting industry transformation and innovation, strengthening R&D, and expanding international cooperation. As the founder of Beijing Tide Pharmaceutical, , she led Beijing Tide to commit to innovation in R&D, production, marketing, and management, and to vigorously expand international cooperation to promote the rapid development of the high-tech medical industry in China, with her unique insight of "focusing on innovation to achieve leapfrog development for the enterprise" Under her leadership, Beijing Tide has achieved tremendous growth, riding on internationalization and innovation, becoming a leading domestic enterprise in the R&D, production, and sales of targeted drugs. It has been included in the "Top 100 Enterprises in Chinese Pharmaceutical Industry" for years.
Over the years, Ms. Cheng is committed to facilitating communication and trade between Mainland and Hong Kong, and has done remarkable work for the purposes of promoting national cohesion and bilateral cooperation. She is also a devoted charity supporter, actively participating in and caring for community philanthropy. Public offices held by Ms. Cheng include being the founding chairwoman of the Hong Kong China Friendship Association, the founding president of the council of Hong Kong Belt & Road General Chamber of Commerce, the past chairwoman of the Friendship Association of the Chinese People’s Political Consultative Conference (Hong Kong Provincial Committee), a member of the Eighth, Ninth, Tenth, Eleventh and Twelfth Standing Committees of the Shaanxi Province Chinese People's Political Consultative Conference.
The distinguished community services provided by Ms. Cheng is well recognized by various sectors. She has been appointed as a Justice of the Peace (JP) and awarded the Silver Bauhinia Star (SBS) by the Government of Hong Kong SAR. and awarded by a number of organizations honours, such as the 4th Beijing "Jinghua Award", the 11th Qingdao "Qindao Award", "2020 Advanced Individual in the Fight Against the COVID-19 Pandemic", "2019 and 2020 Pioneer in Pharmaceutical Industry in China", and one of the "Top 10 Leaders in Economy in China for 2019".
*Portrait rights belong to the individual. Unauthorized use is prohibited.
-
Sino Biopharm Donates HK$10 Million in Cash and Medicine for Emergency Relief of Tai Po Fire in Hong Kong 2025.11
On November 26, a sudden fire broke out at Wang Fuk Court in Tai Po District, New Territories, Hong Kong, drawing concern from across the nation.View > -
Senior Chairman of Charoen Pokphand Group Mr. Dhanin Chearavanont Attended the 80th Anniversary of the Victory in the Chinese People's War of Resistance, Leaders of CP Pharmaceutical Group Were Invited to Observe the Ceremony 2025.09
On the morning of September 3, a grand ceremony commemorating the 80th anniversary of the victory in the Chinese People's War of Resistance Against Japanese Aggression and the World Anti-Fascist War was held in Tiananmen Square, Beijing.View > -
Sino Biopharm Reports Strong H1 Results: Net Profit Doubles, Innovation Drives Record Revenue of RMB 17.57 Billion 2025.08
On the afternoon of August 18, Sino Biopharm (1177.HK) held its interim results conference in Hong Kong, continuing its outstanding performance of high growth in revenue and net profit: In the first half of 2025, the company's revenue reached RMB 17.57 billion, with a year-on-year increase of 10.7%; the net profit attributable to owners of the parent from continuing operations was RMB 3.39 billion, with a substantial increase of 140.2%; and the adjusted net profit attributable to owners of the parent was RMB 3.09 billion, with a year-on-year increase of 101.1%.View >